Skip to main content

Midterm elections provide a surprising lift for drug stocks, with one analyst calling outcome a ‘best-case scenario’

Pharmaceutical prices are one of the few potentially bipartisan issues for this new Congress. But that didn’t stop policy experts and analysts from calling the latest results a win.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.